X4 Pharmaceuticals Inc

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026